Navigation Links
ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
Date:10/5/2009

s is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal conditions. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:

    ThromboGenics
    Dr. Steve Pakola, CMO
    Tel: +
'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 North Shore ... York City, partnered with GI Energy, one of the nation’s ... a $13 million upgrade of its 43-year-old CHP system. The ... and in an effort to extend the life of the ... generators and associated electrical and heat recovery equipment, while maintaining ...
(Date:7/31/2014)... CollabRx, Inc. (NASDAQ: CLRX), a leading provider ... today announced that it will hold an investor conference ... financial results for the first quarter of fiscal 2015 ... the current fiscal year. , The dial-in number for ... 2014, at 5 p.m. EDT (2 p.m. PDT) is ...
(Date:7/31/2014)... SAN DIEGO and SHENZHEN, China ... Genomics announced today the purchase of an ... genomics organization. BGI selected BioNano,s platform to enable comprehensive ... vastly improved assemblies for various organisms of interest, including ... BGI will partner together to develop new methods for ...
(Date:7/31/2014)... The global market for molecular diagnostics is expected to ... new study by Grand View Research, Inc. Growing demand ... of advanced cancer diagnostic technologies are expected to be ... years. Moreover, the growing global base of geriatric population ... triggering lifestyle habits such as smoking and excessive alcohol ...
Breaking Biology Technology:North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2BioNano Genomics Announces the Purchase of the Irys System by BGI 2BioNano Genomics Announces the Purchase of the Irys System by BGI 3BioNano Genomics Announces the Purchase of the Irys System by BGI 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5
... April 1, 2008 Cardium Therapeutics,(Amex: ... Therapies announced today that,InnerCool has entered into ... (Euromed), a leading distributor of cardiology,medical products. ... will have,exclusive marketing, sales and distribution rights ...
... April 1, 2008 Piedmont Heart Institute (PHI),expands ... cardiovascular,physician practice, Cardiology of Georgia, P.C. (COG), through ... 2008. With eight,locations including Buckhead, Canton, Fayetteville and ... under the Piedmont Heart Institute and an,important addition ...
... 1, 2008 ,Neurobiological Technologies, Inc. (NTI(R)) (Nasdaq: NTII ... Loar has been appointed Chief,Financial Officer. Mr. Loar will ... joins the company from Osteologix, where he has served,as ... proven track record as a chief financial officer, and ...
Cached Biology Technology:Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Piedmont Heart Institute Welcomes Cardiology of Georgia 2Piedmont Heart Institute Welcomes Cardiology of Georgia 3Piedmont Heart Institute Welcomes Cardiology of Georgia 4Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 2Neurobiological Technologies Appoints Matthew M. Loar as Chief Financial Officer 3
(Date:7/30/2014)... University is paving the way for a breakthrough ... military troops exposed to poisonous chemicalsparticularly those in ... in the current issue of the journal ... which are compounds commonly used in pesticides and ... NYU School of Engineering Associate Professor of Chemical ...
(Date:7/30/2014)... Carroll,s Through the Looking Glass, collaborators from the ... improved a 35-year-old ecology model to better understand ... years. , The new model, called a mean ... Effect," an evolutionary hypothesis introduced by Lee Van ... must constantly increase their fitness (or ability to ...
(Date:7/30/2014)... American Chemical Society (ACS) announced today that David L. ... ACS Biomaterials Science & Engineering as editor-in-chief. With ... the new journal will feature high-quality research in the ... or naturally derived materials that interact with living or ... it reflects the tremendous growth in the field of ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3ACS Biomaterials Science & Engineering: Brand-new journal launches in 2015, names editor 2
... interdisciplinary perspective. Presenters at the National Academy of Sciences, ... ways to identify, encourage, and support advances in climate ... other fields. In addition, U.S. Secretary ... Sackler Lecture beginning at 6 p.m. on March 31 ...
... Providing further understanding of the link between low birth ... deprived newborns are "programmed" to eat more because they ... that controls food intake, according to an article published ... The study by a team of researchers at Los ...
... of people commit suicide worldwide each year, researchers and ... person,s likelihood of thinking about or trying to commit ... Hospital del Mar Research Institute (IMIM) has participated, has ... suicides. "It is of key importance to identify suicidal ...
Cached Biology News:Study provides explanation for connection between low birth weight and obesity later in life 2First international index developed to predict suicidal behavior 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
Water Distilled (Gibco™) is membrane filtered and endotoxin screened....
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
Biology Products: